MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02352883

Recruitment Status : Active, not recruiting

First Posted : February 2, 2015

Last Update Posted : June 22, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

National Cancer Institute (NCI)

Eastern Cooperative Oncology Group

Information provided by (Responsible Party):

Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	November 2027
Estimated Study Completion Date :	November 2027

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lehman CD, Gatsonis C, Romanoff J, Khan SA, Carlos R, Solin LJ, Badve S, McCaskill-Stevens W, Corsetti RL, Rahbar H, Spell DW, Blankstein KB, Han LK, Sabol JL, Bumberry JR, Gareen I, Snyder BS, Wagner LI, Miller KD, Sparano JA, Comstock C. Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2019 Jul 1;5(7):1036-1042. doi: 10.1001/jamaoncol.2018.6269.

To Top